Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GR 79236

Drug Profile

GR 79236

Latest Information Update: 03 Jul 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia; Pain; Reperfusion injury; Type 2 diabetes mellitus

Most Recent Events

  • 03 Jul 2003 A clinical study has been added to the adverse events and Headache and migraine pharmacodynamics sections
  • 24 Aug 1999 Discontinued-I for Hyperlipidaemia in United Kingdom (Unknown route)
  • 24 Aug 1999 Discontinued-I for Pain in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top